Market News (Page 15) - TendieTensor

Market News Page 15 of 283 • 7,059 articles

Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End

Benzinga • Prnewswire

Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End

01/08/2026 09:00 AM • Kazia Therapeutics announced that its CEO will participate in the J.P. Morgan Healthcare Conference week in San Francisco. The company expects to provide a clinical and translational update before month-end from its Phase 1b trial evaluating paxalisib in advanced triple-negative breast cancer, including additional clinical response observations and expanded biomarker analyses. Kazia also plans to provide the first update on its potential first-in-class PD-L1 protein degrader program.

LEN - Consistent investment by Berkshire across two share classes, no specific growth details provided
KZIA - The company is well-capitalized following recent financing and has multiple near-term catalysts including anticipated clinical updates for paxalisib in triple-negative breast cancer with positive biomarker data showing CTC reductions, plus a new first-in-class PD-L1 protein degrader program update. The CEO's participation in JPM Week and strong strategic momentum indicate positive momentum.

#Kazia Therapeutics #J.P. Morgan Healthcare Conference #paxalisib #triple-negative breast cancer #Phase 1b trial #clinical update #PD-L1 protein degrader #PI3K/mTOR inhibitor #biomarker analysis

11:11 Systems Successfully Completes Acquisition of Ntirety

GlobeNewswire Inc. • Not Specified

11:11 Systems Successfully Completes Acquisition of Ntirety

01/08/2026 09:00 AM • 11:11 Systems announced the acquisition of Ntirety, marking its sixth purchase of an authorized VMware partner. The acquisition comes as Broadcom has optimized the VMware Cloud Service Provider ecosystem. 11:11 Systems, now one of the largest private VCSP partners with over 6,000 customers, continues to consolidate the market following previous acquisitions of iland Cloud, Green Cloud Defense, Unitas Global, Sungard Availability Services, and Faction.

SIRI - High dividend yield of 5%, low forward price-to-earnings ratio, but limited growth potential
AVGO - Broadcom's optimization of the VCSP program is achieving its stated goal of consolidating around core competent partners like 11:11, though this is a strategic business decision rather than a direct company achievement.

#acquisition #VMware Cloud Service Provider #managed infrastructure #cloud services #consolidation #Broadcom

GlobeNewswire Inc. • Not Specified

11:11 Systems Successfully Completes Acquisition of Ntirety

01/08/2026 09:00 AM • 11:11 Systems announced the acquisition of Ntirety, marking its sixth purchase of an authorized VMware partner. The acquisition comes as Broadcom has optimized the VMware Cloud Service Provider ecosystem, prompting former VCSPs to seek partnerships or consolidation. 11:11 Systems, now one of the largest private VMware Cloud Service Providers with over 6,000 customers, continues to expand its global cloud platform and expertise through strategic acquisitions.

DPZ - Increased stake by Berkshire, but no specific growth indicators mentioned
AVGO - Broadcom's optimization of the VCSP program is driving consolidation among partners. While this reflects strategic focus on core partners like 11:11, the sentiment is neutral as it represents a business restructuring rather than a direct positive or negative development for Broadcom itself.

#acquisition #VMware Cloud Service Provider #managed infrastructure #cloud services #consolidation #Broadcom #VCSP ecosystem

Bank of South Carolina Corporation Announces Annual and Fourth Quarter Earnings

Benzinga • Prnewswire

Bank of South Carolina Corporation Announces Annual and Fourth Quarter Earnings

01/08/2026 09:00 AM • Bank of South Carolina Corporation reported record annual earnings of $7.9 million for 2025, up 17.15% year-over-year, with earnings per share of $1.45 basic and $1.41 diluted. The bank achieved a return on average assets of 1.38% and return on average equity of 13.83%, while completing a $2 million stock repurchase program.

CB - Low forward earnings multiple, consistent insurance sector investment
BKSC - The company reported record annual earnings with 17.15% year-over-year growth, all-time highs in net income and EPS, improved returns on assets and equity, and successful completion of a $2 million share repurchase program, demonstrating strong financial performance and shareholder-friendly capital allocation.

#earnings #profitability #return on assets #return on equity #stock repurchase #South Carolina banking

Zoom Opens Nominations for First U.S. Solopreneur 50 List, Recognizing AI-First Solo Business Leaders

GlobeNewswire Inc. • Na

Zoom Opens Nominations for First U.S. Solopreneur 50 List, Recognizing AI-First Solo Business Leaders

01/08/2026 09:00 AM • Zoom launched the Solopreneur 50 List (ZSP50), a recognition and grant program honoring 50 solo business leaders across the U.S. who leverage AI to scale their ventures. Nominations are open until February 13, 2026. The initiative highlights that 82% of U.S. small businesses operate without employees, with 64% of solopreneurs stating they couldn't operate without AI. Survey data shows 91% of small businesses achieved ROI on AI investments within one year, with AI helping reduce costs (82%), increase customer acquisition (91%), and improve retention (87%).

GOOGL - Strong AI growth potential, leadership in robotaxi market, promising extended reality and quantum computing developments
UPWK - Upwork is mentioned as a research partner in the survey of small businesses and solopreneurs regarding AI adoption. While the partnership indicates relevance to the solopreneur ecosystem, the mention is limited to survey collaboration with no direct business impact or strategic implications discussed.

#solopreneur #AI integration #small business #grant program #recognition #entrepreneurship #AI adoption #business scaling

Qatar Is Quietly Becoming The Middle East's AI Superpower

Benzinga • Ahmad Shadid

Qatar Is Quietly Becoming The Middle East's AI Superpower

01/08/2026 08:42 AM • While Saudi Arabia and the UAE pursue flashy, large-scale AI projects, Qatar is taking a more strategic approach by investing in foundational AI infrastructure and confidential computing. A $20 billion partnership between Qatar Investment Authority and Brookfield focuses on data centers and compute capacity, while Qatar hosts the Gulf's first confidential AI computing facility. This patient, infrastructure-focused strategy positions Qatar to become the region's AI leader by prioritizing trust, compliance, and data security over headline-grabbing announcements.

LEN.B - Consistent investment by Berkshire across two share classes, no specific growth details provided
BN - Partner in the $20 billion Qatar AI infrastructure deal; positioned to benefit from estimated $7 trillion in global AI infrastructure spending over the next decade.

#AI infrastructure #confidential computing #data centers #Middle East AI #enterprise AI #data security #regulatory compliance

Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Drop— AZZ, Northrop Grumman, Immuneering In Focus (UPDATED)

Benzinga • Rishabh Mishra

Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Drop— AZZ, Northrop Grumman, Immuneering In Focus (UPDATED)

01/08/2026 08:41 AM • U.S. stock futures declined on Thursday with investors awaiting Supreme Court ruling on tariffs and December jobs reports. AZZ surged on strong earnings, Northrop Grumman jumped on defense spending proposals, while Immuneering tumbled on disappointing trial data and Phathom dropped following stock offering announcement. Constellation Brands rose on better-than-expected earnings.

AZZ - Stock rose 2.8% in premarket following upbeat third quarter earnings report and maintains stronger price trends across short, medium, and long terms.

#stock market futures #S&P 500 #Dow Jones #tariffs #jobs report #defense spending #earnings #biotech #pharmaceuticals

Lockheed Martin Pops as Traders Price a Bigger Defense Spend Cycle

Investing.com • Timothy Fries

Lockheed Martin Pops as Traders Price a Bigger Defense Spend Cycle

01/08/2026 08:36 AM • Lockheed Martin stock surged 7.77% in premarket trading after President Trump announced a $1.5 trillion defense budget for 2027, a 50% increase from the previously planned $1 trillion. The announcement triggered a broader rally across the defense sector, with other major contractors like Northrop Grumman, RTX, and Kratos Defense also posting significant gains.

AMZN - Strategic partner supporting democratization of AI access for life sciences organizations
LMT - Stock surged 7.77% in premarket trading to $535.22 following announcement of massive $1.5 trillion defense budget increase, demonstrating strong investor confidence in increased defense spending.

#defense spending #Lockheed Martin #Trump administration #military budget #aerospace contractors #stock rally

How Micron Technology Stock Soared 21% Last Month

The Motley Fool • Anders Bylund

How Micron Technology Stock Soared 21% Last Month

01/08/2026 08:33 AM • Micron Technology's stock jumped 21% in December 2025 following strong Q1 2026 earnings driven by AI-driven demand for memory chips. The company reported 56.6% year-over-year revenue growth and a quadrupling of earnings per share, with net income surging from $1.87 billion to $5.24 billion. Despite reaching all-time highs, the stock trades at a valuation discount (8.4x forward earnings) compared to other AI stocks, suggesting further upside potential as AI demand for memory chips remains robust.

MU - Strong Q1 2026 earnings beat expectations with 56.6% YoY revenue growth, net income quadrupling, and free cash flow skyrocketing. Stock at all-time highs with attractive valuation at 8.4x forward earnings. AI demand for memory chips expected to sustain growth momentum.

#Micron Technology #AI demand #memory chips #semiconductor #earnings growth #stock valuation #high bandwidth memory

OneStream To Go Private In $24-A-Share Deal, Analysts See Limited Upside

Benzinga • Priya Nigam

OneStream To Go Private In $24-A-Share Deal, Analysts See Limited Upside

01/08/2026 08:31 AM • OneStream Inc (NASDAQ:OS) announced it will be taken private by Hg Capital at $24 per share. Analysts view the deal as fairly valued with limited upside, noting that majority shareholder KKR was seeking an exit. The acquisition is unlikely to receive a higher bid. Competitors BlackLine and Workiva saw stock gains following the announcement.

EDAP - The company is showcasing its leadership in robotic energy-based therapies, highlighting growth in Focal One® system placements and presenting at a prominent healthcare conference, indicating confidence and market expansion
OS - Deal priced at $24/share is considered fair value with modest upside potential. Analysts downgraded ratings but acknowledged the valuation is acceptable given current growth rates and unlikely to improve.

#take-private #acquisition #valuation #SaaS #software #M&A

Skyharbour Announces Additional Uranium Property Staking Increasing Total Portfolio to Over 662,000 Hectares in the Athabasca Basin, Saskatchewan

GlobeNewswire Inc. • Skyharbour Resources Ltd.

Skyharbour Announces Additional Uranium Property Staking Increasing Total Portfolio to Over 662,000 Hectares in the Athabasca Basin, Saskatchewan

01/08/2026 08:00 AM • Skyharbour Resources has expanded its uranium exploration portfolio in Saskatchewan's Athabasca Basin by acquiring 40 new prospective uranium exploration claims through low-cost staking, adding 64,913 hectares to its holdings and bringing the total portfolio to 662,887 hectares across 43 projects. The company will advance its flagship Russell Lake project with joint venture partner Denison Mines and its 100% owned Moore Project, while using new claims as part of its prospect generator business to attract strategic partners.

DNN - Denison Mines is positioned as a strategic partner in Skyharbour's co-flagship Russell Lake project joint venture, indicating collaborative advancement of high-potential uranium assets in the Athabasca Basin.

#uranium exploration #Athabasca Basin #Saskatchewan #property staking #mineral claims #joint venture #prospect generator #unconformity-related uranium #exploration portfolio

AirJoule Technologies Begins Net Zero Innovation Hub for Data Centers Program and Advances Commercial Deployment with Google, Microsoft, and Industry Leaders

GlobeNewswire Inc. • Airjoule Technologies Corporation

AirJoule Technologies Begins Net Zero Innovation Hub for Data Centers Program and Advances Commercial Deployment with Google, Microsoft, and Industry Leaders

01/08/2026 08:00 AM • AirJoule Technologies has officially launched its participation in the Net Zero Innovation Hub for Data Centers program, selected as one of three winners from over 70 applicants. The company will collaborate with major data center operators including Microsoft, Google, Data4, Vertiv, Schneider Electric, and Danfoss to deploy water-from-air systems that utilize waste heat for sustainable data center operations. A testbed facility deployment in Denmark is expected in summer 2026.

USARW - Company is strategically expanding its capabilities, securing critical supply chain links, and diversifying its rare earth metal production outside of China
AIRJ - Company achieved significant milestone by being selected as one of only three winners from 70+ applicants for the Net Zero Innovation Hub program. Secured partnerships with major industry leaders (Microsoft, Google, Vertiv, Schneider Electric, Danfoss) and is advancing toward commercial deployment with expected testbed installation in summer 2026. This represents substantial progress in commercialization strategy.

#water-from-air technology #data center sustainability #waste heat utilization #Net Zero Innovation Hub #commercial deployment #water stress #industrial water solutions

Korro to Present at the 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire Inc. • Na

Korro to Present at the 44th Annual J.P. Morgan Healthcare Conference

01/08/2026 08:00 AM • Korro Bio announced that CEO Ram Aiyar will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026. The biopharmaceutical company is focused on developing RNA editing genetic medicines for rare and prevalent diseases. A live webcast will be available on their investor relations website.

KRRO - The article is primarily an announcement of a conference presentation with standard corporate disclosure information. While the company is advancing its pipeline (KRRO-110 mentioned), the article lacks specific clinical or financial results that would indicate positive or negative momentum. The tone is informational rather than highlighting significant achievements or setbacks.

#RNA editing #genetic medicines #biopharmaceutical #J.P. Morgan Healthcare Conference #KRRO-110 #Alpha-1 Antitrypsin Deficiency

Bone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook

GlobeNewswire Inc. • Na

Bone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook

01/08/2026 08:00 AM • Bone Biologics announced 2025 achievements including extending rhNELL-1 shelf life to 24 months, completing a $5 million public offering, filing new patent applications, and maintaining Nasdaq compliance. The company plans to continue advancing its NB1 clinical trial in 2026 with focus on patient enrollment completion and operational readiness.

BApA - Mentioned as a previous workplace of Mike Ross, with no significant positive or negative context
BBLG - The company demonstrated solid operational progress in 2025 with multiple achievements: extended product shelf life (24 months), successful capital raise ($5M), patent filings, Nasdaq compliance maintenance, and clear 2026 clinical development roadmap. These milestones indicate effective execution and positioning for continued advancement of their lead product candidate NB1.

#rhNELL-1 #NB1 #bone graft #spine fusion #clinical trial #shelf life extension #capital raising #patent portfolio #Nasdaq compliance #orthobiologic

CCC Intelligent Solutions Introduces OEM Repair Certification Management Solution

GlobeNewswire Inc. • Ccc Intelligent Solutions Inc.

CCC Intelligent Solutions Introduces OEM Repair Certification Management Solution

01/08/2026 08:00 AM • CCC Intelligent Solutions announced that Nissan will be the first automaker to participate in the newly launched CCC OEM Link Network, designed to streamline OEM collision certification programs. Through this partnership, CCC will manage certified network operations for Nissan's approximately 2,000 certified collision repair facilities across the U.S., handling shop audits, billing, and communications. The initiative aims to reduce administrative burden for repair shops while helping Nissan maintain network consistency and strengthen brand reputation through quality repairs.

NSANY - Nissan's participation in the OEM Link Network demonstrates commitment to quality repairs and brand reputation. The partnership reduces administrative burden for their certified repair network, improves ROI visibility, and enables expansion of their certified program. Nissan is already increasing job referrals to certified shops, indicating confidence in the program's value.

#collision repair certification #OEM Link Network #certified repair network #vehicle repair quality #advanced vehicle technologies #shop administration #repair network expansion

Northern Technologies International Corporation Reports Financial Results for First Quarter Fiscal 2026

GlobeNewswire Inc. • Northern Technologies International Corporation

Northern Technologies International Corporation Reports Financial Results for First Quarter Fiscal 2026

01/08/2026 08:00 AM • Northern Technologies International Corporation (NTIC) reported Q1 FY2026 results with consolidated net sales reaching a quarterly record of $23.3 million, up 9.2% year-over-year. While ZERUST® oil and gas sales surged 58.1% and NTIC China grew 23.5%, gross profit margin declined 230 basis points to 36.0% due to supplier lead-time issues. Net income fell to $238,000 from $561,000 despite record sales, primarily due to higher operating expenses and an unusually high effective tax rate of 34.4%. Management expects profitability to improve in subsequent quarters as sales growth outpaces operating expense growth.

USARW - The company is strategically expanding its capabilities by acquiring a key metal manufacturer, which enhances its supply chain, provides access to critical relationships, and supports domestic rare earth production
NTIC - Mixed results with positive revenue growth (9.2% increase to record sales) and strong performance in key segments (oil & gas +58.1%, China +23.5%), but offset by declining profitability (net income down 58% YoY), compressed gross margins (down 230 bps), and elevated tax rates. Management's optimistic forward guidance and expectations for margin recovery provide some positive outlook, but current quarter performance shows profitability challenges despite top-line strength.

#corrosion inhibiting products #ZERUST® #Natur-Tec® #gross margin decline #oil and gas segment #China operations #operating expenses #tax rate #working capital

Blue Star Families Welcomes New Advisory Board Members to Advance Military Family Initiatives

GlobeNewswire Inc. • Blue Star Families

Blue Star Families Welcomes New Advisory Board Members to Advance Military Family Initiatives

01/08/2026 08:00 AM • Blue Star Families, the nation's largest nonprofit supporting military and veteran families, announced the appointment of seven new members to its National Advisory Board on January 8, 2026. The new members include leaders from Princeton University, TIME, Salesforce, the Department of Defense, the National Governors Association, Chobani, and Mastercard, bringing expertise in communications, media, defense policy, and corporate impact.

CRM - Edward Felsenthal, a senior advisor in the office of the CEO at Salesforce, was appointed to the advisory board, indicating the company's commitment to supporting military and veteran families through leadership involvement in philanthropic initiatives.

#military families #veteran support #nonprofit #advisory board #federal policy #corporate partnerships

Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases

GlobeNewswire Inc. • Na

Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases

01/08/2026 07:00 AM • Entrada Therapeutics reported progress across its RNA-based therapeutic pipeline, with multiple clinical programs in development for Duchenne muscular dystrophy (DMD) and expansion into ocular diseases. The company expects to report data from ELEVATE-44-201 in Q2 2026 and ELEVATE-45-201 in mid-2026, initiate a Phase 1/2 study for ENTR-601-50 by end of 2026, and submit regulatory applications for ENTR-601-51 in 2026. Entrada selected ENTR-801 as its first clinical candidate for Usher syndrome type 2A treatment and plans to nominate a second ocular candidate in 2026. The company maintains cash runway into Q3 2027.

TRDA - Company demonstrated significant pipeline progress with multiple clinical programs advancing on schedule, FDA rare pediatric disease designation granted, expansion into new therapeutic area (ocular diseases), and adequate cash runway through Q3 2027. Multiple data readouts expected in 2026 represent key value inflection points.

#RNA-based therapeutics #Duchenne muscular dystrophy #Usher syndrome #exon skipping #clinical trials #ocular diseases #neuromuscular diseases #Phase 1/2 studies #regulatory approval

VarmX and Rentschler Biopharma partner to advance novel coagulation therapy toward Phase 3 and commercialization

GlobeNewswire Inc. • Na

VarmX and Rentschler Biopharma partner to advance novel coagulation therapy toward Phase 3 and commercialization

01/08/2026 07:00 AM • VarmX and Rentschler Biopharma expanded their collaboration to manufacture VMX-C001, a novel coagulation therapy, for Phase 3 development and commercialization. The drug, which restores blood coagulation in patients on FXa DOACs requiring urgent surgery, has received FDA Fast Track Designation and PMDA Phase 1 waiver. Manufacturing will transition from Laupheim, Germany to Milford, MA, with Phase 3 trials expected to begin in early 2026.

CSLLY - CSL's strategic collaboration and option agreement with VarmX (signed September 2025) provides exposure to a novel coagulation therapy with strong regulatory momentum and significant commercial potential in a large patient population requiring emergency surgery.

#VMX-C001 #coagulation therapy #Phase 3 trial #FXa DOACs #manufacturing partnership #FDA Fast Track Designation #contract manufacturing

Beacon Therapeutics Announces Closing of Oversubscribed Series C Financing for Over $75 Million

GlobeNewswire Inc. • Na

Beacon Therapeutics Announces Closing of Oversubscribed Series C Financing for Over $75 Million

01/08/2026 07:00 AM • Beacon Therapeutics, a clinical-stage biotechnology company focused on ocular gene therapies, announced a Series C funding round of over $75 million led by Life Sciences at Goldman Sachs Alternatives, with participation from the Retinal Degeneration Fund. The funds will support commercialization of laru-zova for X-linked retinitis pigmentosa treatment, with pivotal trial data expected in H2 2026, and advance development of pipeline candidates for geographic atrophy and inherited cone rod dystrophy.

GS - Goldman Sachs' Life Sciences division led the Series C round and appointed a Managing Director to Beacon's Board, signaling confidence in the company's strategy and potential for value creation in the gene therapy space.

#gene therapy #Series C funding #X-linked retinitis pigmentosa #laru-zova #ocular diseases #clinical-stage biotech #VISTA trial #commercialization

AtaiBeckley Provides Update and Outlook for 2026 Ahead of J.P. Morgan Healthcare Conference

GlobeNewswire Inc. • Ataibeckley Inc

AtaiBeckley Provides Update and Outlook for 2026 Ahead of J.P. Morgan Healthcare Conference

01/08/2026 07:00 AM • AtaiBeckley Inc (NASDAQ: ATAI), formed from the merger of atai Life Sciences and Beckley Psytech, announced its 2026 outlook ahead of the J.P. Morgan Healthcare Conference. The company reported positive Phase 2b data for BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression, with Phase 3 trials expected in Q2 2026. Additional milestones include Phase 2 data for VLS-01 (DMT buccal film) in H2 2026 and EMP-01 (oral R-MDMA) for social anxiety disorder in Q1 2026. The company completed its redomiciliation to the United States in December 2025 and was added to the NASDAQ Biotechnology Index.

VYLD - Participating in investment round as an institutional investor without additional context
ATAI - Company demonstrated positive Phase 2b clinical trial results for lead candidate BPL-003 with rapid and durable antidepressant effects, announced advancement to Phase 3 trials, secured patent protection extending to 2043, completed strategic redomiciliation to improve operational efficiency, achieved inclusion in NASDAQ Biotechnology Index, and has sufficient financial runway through 2029. These developments indicate strong clinical progress and corporate momentum.

#clinical-stage biotechnology #treatment-resistant depression #mental health treatments #Phase 2b clinical trial #Phase 3 trials #redomiciliation #NASDAQ Biotechnology Index #drug development pipeline

Lexeo Therapeutics Announces Research Collaboration to Explore Targeted Cardiac Delivery of AAV Gene Therapy

GlobeNewswire Inc. • Na

Lexeo Therapeutics Announces Research Collaboration to Explore Targeted Cardiac Delivery of AAV Gene Therapy

01/08/2026 07:00 AM • Lexeo Therapeutics announced a research collaboration with Johnson & Johnson to investigate localized cardiac delivery of AAV gene therapy using Impella heart pump technology. The partnership aims to improve the efficacy and safety of gene therapy for genetically mediated cardiovascular diseases by concentrating viral delivery to the heart while reducing required AAV doses.

JPMpM - Participating in investment round as an institutional investor without additional context
LXEO - The company announced a strategic collaboration with a major pharmaceutical leader (Johnson & Johnson) to advance its cardiac gene therapy platform. This partnership validates Lexeo's technology, provides access to complementary expertise and established cardiovascular technologies, and accelerates development of preclinical cardiac targets, which are positive indicators for the company's pipeline and market potential.

#AAV gene therapy #cardiac delivery #Impella heart pumps #cardiovascular diseases #genetic medicine #research collaboration

Kinross to provide update on Round Mountain Phase X, Kettle River-Curlew and Bald Mountain Redbird 2 projects

GlobeNewswire Inc. • Na

Kinross to provide update on Round Mountain Phase X, Kettle River-Curlew and Bald Mountain Redbird 2 projects

01/08/2026 07:00 AM • Kinross Gold Corporation will provide an update on three major projects (Round Mountain Phase X, Kettle River-Curlew, and Bald Mountain Redbird 2) during a virtual presentation on January 15, 2026. The company also recently received a Baa2 rating upgrade from Moody's and announced a $500 million redemption of Senior Notes.

JPMpL - Participating in investment round as an institutional investor without additional context
KGC - The company is providing updates on multiple development projects, received a credit rating upgrade from Moody's (Baa2), and is redeeming debt, all indicating financial strength and operational progress.

#Kinross Gold #Round Mountain Phase X #Kettle River-Curlew #Bald Mountain Redbird 2 #project update #Moody's upgrade #Senior Notes redemption #gold mining

Aurora Mobile Congratulates Zhipu on Successful Hong Kong Listing

GlobeNewswire Inc. • Aurora Mobile Limited

Aurora Mobile Congratulates Zhipu on Successful Hong Kong Listing

01/08/2026 07:00 AM • Aurora Mobile extended congratulations to Zhipu (Knowledge Atlas Technology) on its successful listing on the Hong Kong Stock Exchange on January 8, 2026. Zhipu, recognized as the world's first publicly listed company with a core business centered on AGI foundational models, priced its offering at HK$116.20 per share and raised approximately HK$4.35 billion. Aurora Mobile highlighted growing demand for high-concurrency messaging, mission-critical communication reliability, and secure identity verification solutions to support AI-driven enterprises.

JPMpK - Participating in investment round as an institutional investor without additional context
JG - Aurora Mobile is positioning itself as a key infrastructure provider for AI-driven enterprises, highlighting growing demand for its messaging and security solutions. The company is leveraging the AI boom to expand its service offerings and market relevance.

#artificial general intelligence #AGI foundational models #Hong Kong Stock Exchange listing #customer engagement #digital infrastructure #messaging services #identity verification #two-factor authentication

Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria

GlobeNewswire Inc. • Na

Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria

01/08/2026 07:00 AM • Jasper Therapeutics reported positive updated clinical data from its BEACON Phase 1b/2a study and open-label extension study of briquilimab for chronic spontaneous urticaria (CSU). The drug demonstrated rapid disease control with 67% of additional BEACON patients achieving complete response at 12 weeks and 75% of CSU participants in the extension study achieving complete response or well-controlled disease. Safety profile remained favorable with low-frequency, predominantly low-grade adverse events. The company plans to initiate a Phase 2b study in the second half of 2026.

JPMpJ - Participating in investment round as an institutional investor without additional context
JSPR - The company reported strong clinical efficacy data with high response rates (67-75%), favorable safety profile with no dose-limiting toxicities, and sufficient data to advance to Phase 2b studies. Leadership expressed confidence in the drug's potential for a differentiated product profile in chronic urticaria, supporting continued clinical development momentum.

#briquilimab #chronic spontaneous urticaria #CSU #KIT inhibitor #mast cell depletion #Phase 2b trial #clinical efficacy #drug safety